RxDoctor Payments Data

William Haney, MD

Internal Medicine · Louisville, KYNPI 1538250147

Payments from drug & device makers

$4,675in general payments, 2019–2025

Across 230 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$572
  • AbbVie$431
  • Sunovion Pharmaceuticals Inc.$355
  • Novo Nordisk$328
  • Pfizer$316
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,64599%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,675 in reported general payments places this provider in the 85th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$34,548
Medicare patients
100
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide69$83,867
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$43,092
EliquisApixaban44$41,835
OzempicSemaglutide28$28,108
XareltoRivaroxaban12$18,036
JardianceEmpagliflozin20$17,340
Janumet XrSitagliptin Phos/Metformin Hcl18$15,358
Xigduo XrDapaglifloz Propaned/Metformin14$13,249
SaphrisAsenapine Maleate13$7,669
InvokanaCanagliflozin12$6,991
JanumetSitagliptin Phos/Metformin Hcl12$6,751
Breo ElliptaFluticasone/Vilanterol11$5,024
Celecoxib28$4,127
Eszopiclone13$3,355
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen125$3,280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$160$83,86769 claims
GileadGenvoya$17$43,09211 claims
PfizerEliquis$316$41,83544 claims
Novo NordiskOzempic$328$28,10828 claims
Johnson & JohnsonXarelto, Invokana$20$25,02724 claims
MerckJanumet Xr, Janumet$132$22,10930 claims
Boehringer IngelheimJardiance$45$17,34020 claims
AbbVieSaphris, Synthroid$431$8,99324 claims
GSKBreo Ellipta$74$5,02411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →